about
Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataABC3 Consensus Commented from the Perspective of the German GuidelinesTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerGerman Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients.Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.ABC3 Consensus: Assessment by a German Group of Experts14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective.13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid.Photodynamic therapy in women with cervical intraepithelial neoplasia using topically applied 5-aminolevulinic acid.Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HIntense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancerOptimal Sequencing of Anti-HER2 Therapy.Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.Lymph node staging in invasive breast cancer.Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast CancerTargeted Therapy for Early and Locally Advanced Breast CancerAdherence to Treatment Guidelines in Breast Cancer Care - a Retrospective Analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie'Systemic Therapy for Women with ErbB2-Positive Breast Cancer: New Options, New Challenges.Lapatinib - Member of a New Generation of ErbB-Targeting Drugs.Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies.Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.Chemosensitivity testing in gynecologic oncology--dream or reality?ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
P50
Q24240202-8A5FF1F7-7FC8-48CD-B3E3-991EEA607560Q26768665-68FC0DFE-8E51-4822-A17D-AF29FB64E997Q27824847-1EC1733E-3AF9-4CF5-AD89-E39A1CF08F07Q27851705-22CAC128-D33C-4E2D-9816-D7BE81FEE797Q27851763-071ADD60-16C6-42B5-97AB-8FDAD6197505Q28237833-6FA283AF-95B3-4406-B33F-E45ED6203F5FQ30313214-A5FEDF79-4051-4236-A45B-5DB122C7AF00Q30313786-6A4163D3-949B-49A2-8208-3339E2EA1B15Q30315301-C87824C4-69F3-4EAF-932D-54183221C6EAQ30315970-974EEA0E-26B5-4CD6-B454-63E3E2DDBF14Q30316383-AF69BD41-B794-4219-8E9E-732A3755F294Q30317450-A2272227-06B3-4F07-A814-D496A5091BECQ30317570-39952C38-8170-44D0-9820-32B563DC3605Q30317734-7A7A2788-435E-4E23-86EE-941D4B8612E4Q30647059-3584D241-1514-48C8-9623-3BAB92AC9DECQ30654795-ED7BA268-130C-49E8-8DD6-FC732F639563Q30758991-A3460944-C81C-47C2-8F6C-87486A553677Q30976616-997D697C-F608-4463-B569-96CEC9E90FCDQ30996906-B3FE33A0-0C13-46DD-914E-3CCDC2F6C0B0Q31141769-90E122DE-9CD6-4312-82E3-F8CCF6CC58CDQ31153453-EEE8858D-D4D1-4316-A2DF-AD8E64906F4DQ33384086-3EE8363E-D336-43D0-AC95-63489F3C8811Q33390705-C8E7B407-1353-4E15-BC6A-4021EBDEE26DQ33406730-94C1D695-555E-47AF-8A3E-6E34DD1ECBBAQ33415041-02ED5A46-5078-4D9E-92D4-C03C5E5DA691Q33533553-63EA2A3B-C51C-4CEB-A420-74E174E3F181Q33574416-4451E44C-341A-4B72-AA8B-7473DCA66992Q33620136-8DC06A37-7DAC-4D86-9CBF-D3E092A33567Q33684818-6BFFB2E5-2FF5-4A7C-AAE8-303BE74BD33EQ33688726-F3B459B1-0A5C-4312-90CC-F5EE18D6D0FFQ34042621-6C7C60D7-40E1-43E3-88CC-3D6DC26833EEQ34095748-A6DE8FF3-EDEF-4AB1-B70A-E2EB34EC7F1EQ34096070-3525DD9E-9DD5-4099-9E3D-6FE90BD8966AQ34096177-BCF69741-5D3A-445F-B4D9-FED65FCBA9F7Q34096218-1960B6EC-8FF5-402A-BDFA-A301A1B0C6ADQ34096228-3DED14C1-8F41-48F9-AE0C-7FB8CF29B387Q34140167-38D8A95B-5D05-4BCF-AD9E-A8B9BFE46778Q34527500-889F9F20-8F73-454C-A846-DFE5D845EC7AQ35045598-AB556F4B-E8AC-425F-92CB-6DA1B8399870Q35045614-747C08FC-64AD-4DE7-9B78-F113B3924B82
P50
description
onderzoeker
@nl
name
Michael Untch
@ast
Michael Untch
@en
Michael Untch
@es
Michael Untch
@sl
type
label
Michael Untch
@ast
Michael Untch
@en
Michael Untch
@es
Michael Untch
@sl
prefLabel
Michael Untch
@ast
Michael Untch
@en
Michael Untch
@es
Michael Untch
@sl
P214
P106
P21
P214
P31
P735
P7859
viaf-6146594